文献速递乳腺癌放疗

乳房切除术后3周大分割放疗对即刻重建植入物失败风险的影响

Implant risk failure in patients undergoing postmastectomy 3-week hypofractionated radiotherapy after immediate reconstruction.
PubMed 文献 · Radiother Oncol · 2021-08-19

该研究评估了接受植入物即刻乳房重建(IBR)并接受大分割(HF)乳房切除术后放疗(PMRT)的患者的重建失败率(RF)。结果显示,在两步法扩张器-植入物(TE/I)组中,放疗患者的主要修正手术(MaRS)率显著高于未放疗患者(12.9% vs 1.6%,p=0.015);而在一步法直接植入(DTI)组中未观察到显著差异(6.7% vs 2.2%,p=0.35)。结论认为,大分割和IMRT用于植入物IBR似乎并未增加RF风险,与文献报道一致。

要点

  • TE/I组放疗后主要修正手术率显著高于未放疗组(12.9% vs 1.6%,p=0.015)。
  • DTI组放疗与未放疗的主要修正手术率无显著差异(6.7% vs 2.2%,p=0.35)。
  • 大分割IMRT用于植入物即刻重建未显示增加重建失败风险。

核心结论

  • 与未放疗患者相比,TE/I组放疗患者的重建失败率更高,而DTI组未观察到统计学显著差异。
  • 使用大分割和IMRT进行植入物即刻重建似乎并未增加重建失败风险,与文献报道一致。

研究设计与样本

  • 研究纳入II-III期乳腺癌患者,接受大分割乳房切除术后放疗(40.05 Gy/15次)并使用调强放疗。
  • 患者按重建方式分为单阶段直接植入(DTI)组和两阶段扩张器-植入物(TE/I)组,并与同期接受相同重建方式的未放疗患者进行匹配。
  • 共107例放疗患者(TE/I组62例,DTI组45例)与107例未放疗患者匹配,中位随访4.2年(范围0.1-6.1年)。

主要发现

  • TE/I组中,放疗患者主要修正手术率为12.9%(8/62),未放疗患者为1.6%(1/62),p=0.015。
  • DTI组中,放疗患者主要修正手术率为6.7%(3/45),未放疗患者为2.2%(1/45),p=0.35。
  • 放疗组总体主要修正手术率为10.3%。
  • DTI组放疗与未放疗的次要修正手术率分别为35.6%和31.1%(p=0.65)。
  • TE/I组放疗与未放疗的次要修正手术率分别为12.9%和8.1%(p=0.38)。

关键数值与推荐

  • 处方剂量为40.05 Gy/15次,照射胸壁及锁骨上/下淋巴结区域。
  • 主要终点重建失败定义为需要主要修正手术(植入物取出或转为自体重建)。
  • 次要终点为次要修正手术率,包括植入物重新定位或更换为另一植入物。

临床怎么用

  • 对于接受植入物即刻重建的患者,TE/I重建方式下放疗可能增加主要修正手术风险,需与患者充分沟通。
  • DTI重建方式下放疗未显示显著增加主要修正手术风险,可作为考虑选项。
  • 大分割IMRT方案(40.05 Gy/15次)未显示增加重建失败风险,支持其在该人群中的应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To evaluate reconstruction failure (RF) rate in patients receiving implant-based immediate breast reconstruction (IBR) and hypofractionated (HF) postmastectomy radiation therapy (PMRT). MATERIALS AND METHODS: Stage II-III breast cancer patients, treated with HF-PMRT using intensity modulated radiotherapy were stratified in two groups according to IBR: single-stage direct-to-implant (DTI-group) and two-stage expander and implant (TE/I-group). Irradiated patients were matched with non-irradiated ones who underwent the same IBR during the same period. Prescription dose was 40.05 Gy/15 fractions to chest wall and infra/supraclavicular nodal region. Primary endpoint was RF defined as the need of major revisional surgery (MaRS) for implant removal or conversion to autologous reconstruction. Secondary endpoint was the rate of minor revisional surgeries (MiRS) including implant repositioning or substitution with another implant. RESULTS: One hundred and seven irradiated patients (62 in TE/I-group, 45 in DTI-group) were matched with 107 non-irradiated subjects. Median follow-up was 4.2 years (0.1-6.1) In the TE/I setting, MaRS was performed in 8/62 irradiated patients (12.9%) of the irradiated TE/I group compared to 1/62 (1.6%) non-irradiated subjects (p = 0.015). In the DTI setting, MaRs occurred in 3/45 irradiated patients (6.7%) compared to 1/45 non-irradiated ones (2.2%) (p = 0.35). Overall MaRS rate was 10.3% in the irradiated group. MiRS was performed in 35.6% and 31.1% of the irradiated and non-irradiated DTI-groups (p = 0.65), respectively, and in 12.9% and 8.1% of the irradiated and non-irradiated TE/I groups (p = 0.38), respectively. CONCLUSIONS: Compared to the non-irradiated counterparts, the TE/I group showed higher rate of RF, while no statistically significant difference was observed for the DTI group. The use of hypofractionation and IMRT to implant-based IBR did not seem to increase the risk of RF which appeared to be in line with the literature.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Rojas DP, Leonardi MC, Frassoni S, et al. Implant risk failure in patients undergoing postmastectomy 3-week hypofractionated radiotherapy after immediate reconstruction. Radiother Oncol. 2021. PMID: 34419507. doi:10.1016/j.radonc.2021.08.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。